Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.69 |
| ▸ | TTR | P02766 | 3/20 | 0.69 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.69 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.69 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.69 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.69 |
| ▸ | ALB | P02768 | 1/20 | 0.69 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.69 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.69 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.69 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.69 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.69 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.69 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.69 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5533948 | 0.84 | PTGS2 (0.75) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| Diclofenac SCHEMBL2799 | 0.82 | PTGS2 (1.00) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| SCHEMBL11814221 | 0.82 | PTGS2 (0.77) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| Diclofenac SCHEMBL996716 | 0.82 | PTGS2 (1.00) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| SCHEMBL4960317 | 0.82 | PTGS2 (0.77) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| Diclofenac SCHEMBL29354260 | 0.82 | PTGS2 (1.00) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| SCHEMBL10031691 | 0.81 | PTGS2 (0.71) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| Diclofenac SCHEMBL6765357 | 0.81 | PTGS2 (0.91) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| SCHEMBL22846863 | 0.81 | PTGS2 (0.71) | PTGS2TTRCXCL8PTGS1AKR1B10 | |
| SCHEMBL30593463 | 0.81 | TTR (0.71) | PTGS2TTRCXCL8PTGS1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173079-A1 | Conjugate Molecules | DIVERSE BIOTECH, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230173079-A1 | Conjugate Molecules | DIVERSE BIOTECH, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-9187427-B2 | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2015-11-17 | — | — | US | disclosed |
| US-20150291590-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES | CELLIX BIO PRIVATE LTD (IN) | 2015-10-15 | — | — | US | disclosed |
| US-20150152060-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT MIGRAINE AND NEUROLOGIC DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| US-20150148306-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | KANDULA MAHESH (IN) | 2015-05-28 | — | — | US | disclosed |
| US-20150148352-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT ANGINA AND CARDIOVASCULAR CONDITIONS | CELLIX BIO PRIVATE LTD (IN) | 2015-05-28 | — | — | US | disclosed |
| US-20150025006-A1 | Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2015-01-22 | — | — | US | disclosed |
| US-8575217-B2 | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-11-05 | — | — | US | disclosed |
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-10-24 | — | — | US | disclosed |
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
| US-20100234452-A1 | Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2010-09-16 | — | — | US | disclosed |
| US-20100234452-A1 | Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291590-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES | KYNU, TKT, SLC5A1 | PTGS2 3327/4885TTR 16/4885CXCL8 4027/4885 |
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | HSD17B14, SORD, GPX4 | PTGS2 169/4885TTR 837/4885CXCL8 1815/4885 |
| US-20100234452-A1 | Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | HSD17B14, SORD, GPX4 | PTGS2 169/4885TTR 837/4885CXCL8 1815/4885 |
| US-20150148352-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT ANGINA AND CARDIOVASCULAR CONDITIONS | KCNH1, TNNT2, TNNC1 | PTGS2 1560/4885TTR 27/4885CXCL8 2456/4885 |
| US-20150148306-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | IAPP, TTR, GPR119 | PTGS2 2226/4885TTR 2/4885CXCL8 1585/4885 |
| US-20150152060-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT MIGRAINE AND NEUROLOGIC DISEASES | PSEN1, APP, PSEN2 | PTGS2 590/4885TTR 39/4885CXCL8 2330/4885 |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | PTGS2 234/4885TTR 2046/4885CXCL8 2704/4885 |
| US-20150025006-A1 | Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | IAPP, AMY2A, GPR119 | PTGS2 426/4885TTR 2294/4885CXCL8 180/4885 |
| US-20230173079-A1 | Conjugate Molecules | CNR2, CNR1, MAG | PTGS2 3632/4885TTR 3894/4885CXCL8 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.